Wilsey Asset Management Inc. raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 11.7% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 402,984 shares of the medical equipment provider’s stock after purchasing an additional 42,231 shares during the period. Zimmer Biomet accounts for approximately 5.7% of Wilsey Asset Management Inc.’s portfolio, making the stock its 8th biggest holding. Wilsey Asset Management Inc.’s holdings in Zimmer Biomet were worth $36,438,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ZBH. Dodge & Cox boosted its position in Zimmer Biomet by 1.3% during the fourth quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after acquiring an additional 290,676 shares during the last quarter. Vanguard Group Inc. lifted its stake in Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after purchasing an additional 192,517 shares in the last quarter. State Street Corp boosted its holdings in shares of Zimmer Biomet by 2.3% during the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after purchasing an additional 195,214 shares during the last quarter. Capital International Investors boosted its holdings in shares of Zimmer Biomet by 11.5% during the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after purchasing an additional 778,467 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a report on Wednesday, April 29th. Truist Financial reissued a “hold” rating and issued a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Barclays cut their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. Finally, Citigroup reduced their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $102.70.

View Our Latest Stock Analysis on Zimmer Biomet

Zimmer Biomet Price Performance

ZBH stock opened at $87.50 on Monday. The business’s 50-day moving average is $86.09 and its two-hundred day moving average is $89.79. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market capitalization of $16.93 billion, a P/E ratio of 22.73, a P/E/G ratio of 2.58 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter last year, the company earned $1.81 earnings per share. The firm’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is presently 24.94%.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Further Reading

• Five stocks we like better than Zimmer Biomet
• Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
• This Under-the-Radar Industrial Is Quietly Powering AI
• Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
• Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINE

Yelin Lapidot Holdings Management Ltd. Raises Position in NVIDIA Corporation $NVDA

NEXT HEADLINE »

Wilsey Asset Management Inc. Raises Stock Holdings in Molson Coors Beverage Company $TAP

You might be interested in: